New York, October 28, 2015 – Cellectis (Alternext: ALCLS – Nasdaq: CLLS) today announced that a series of three production runs of UCART19, its lead TALEN® gene edited product candidate, was performed ...

BIOVECTRA, a part of Agilent Technologies Inc., and Revolution Biomanufacturing Inc. today announced a collaboration that ...

Small biotechs in early development of cell therapies are often surprised by the strictness of commercial manufacturing standards. That’s the view of Luděk Sojka, PhD, CEO of contract developer and ...

TOKYO--(BUSINESS WIRE)--FUJIFILM Corporation (President: Kenji Sukeno) is to invest a total of 3.2 billion yen on its CDMO *1 sites in the U.S.A. and the U.K. in order to accelerate the expansion of ...

GAINESVILLE, Fla., May 28, 2020 /PRNewswire/ -- Arranta Bio ("Arranta"), the leading microbiome contract development and manufacturing organization (CDMO), today announced completion of its process ...

"Abzena and Mabqi partner for drug development solution" was originally created and published by Pharmaceutical Technology, a ...

Contract development and manufacturing organization (CDMO) Abzena has announced the formation of a strategic partnership with ...

CRISPR-Cas9 is one of the most commonly leveraged non-viral editing tools to engineer cells for therapeutics applications. It is a nuclease-based genome editing system which has seen exponential ...

GentiBio, Inc., an emerging biotherapeutics company developing best-in-class engineered regulatory T cells programmed to treat autoimmune, alloimmune, autoinflammatory, and allergic diseases, and ...

Almac is pleased to announce the expansion of our drug product Pharmaceutical Development services with the creation of a new non-GMP formulation development facility and two new analytical ...

Exogenus Therapeutics and Lonza agreed to collaborate on the development of Exo-101, Exogenus’ exosome-based lead candidate. The company specializes in the development of therapeutics based on ...